Abstract The neuroendocrine tumors NETs are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism.
We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year.
The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered.
One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values for all neuroendocrine cancer new treatment 9 cases, marking the disease progression.
New Treatment Options in Pancreatic Cancer
The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms.
The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.